Search Results

You are looking at 11 - 20 of 899 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Overuse of Chest CT in Patients With Stage I and II Breast Cancer: An Opportunity to Increase Guidelines Compliance at an NCCN Member Institution

Barbara Dull, Andrew Linkugel, Julie A. Margenthaler, and Amy E. Cyr

recommended if signs or symptoms of possible distant metastases are present. Diagnostic chest CT is recommended if pulmonary symptoms are present at diagnosis. Several other societies have published similar guidelines. In 2012, ASCO addressed the rising

Full access

Leptomeningeal Metastases: Current Concepts and Management Guidelines

Sajeel Chowdhary and Marc Chamberlain

The authors have no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1 Kaplan JG DeSouza TG Farkash A . Leptomeningeal metastases

Full access

Medullary Thyroid Carcinoma: Management of Lymph Node Metastases

Jeffrey F. Moley

clinical cervical lymph node involvement is as high as 75%, and additional occult metastases may be present. 10 , 11 Clinical complaints, including respiratory difficulty, hoarseness, and dysphagia, are present in approximately 15% of patients with

Full access

Cutaneous Melanoma: Management of Melanoma Brain Metastases and Molecular Testing

Presented by: Douglas B. Johnson, Susan M. Swetter, April K.S. Salama, and Evan Wuthrick

Due to advances in immunotherapies and targeted agents, systemic therapies play an integral role in the up-front management of brain metastases in melanoma. At the same time, the choices for molecular testing have proliferated, particularly gene

Full access

Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases

Neil K. Taunk, Daniel E. Spratt, Mark Bilsky, and Yoshiya Yamada

2003 to 2009. 1 At presentation, 25% of patients will demonstrate metastases, and 25% who undergo nephrectomy for localized disease will ultimately develop recurrent or metastatic tumor. 1 Targeted therapies directed against vascular endothelial

Full access

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma

James J. Harding, Ghaith Abu-Zeinah, Joanne F. Chou, Dwight Hall Owen, Michele Ly, Maeve Aine Lowery, Marinela Capanu, Richard Do, Nancy E. Kemeny, Eileen M. O'Reilly, Leonard B. Saltz, and Ghassan K. Abou-Alfa

Bone metastases are common in hepatocellular carcinoma (HCC), occurring in 25.5% to 38.5% of patients with extrahepatic disease. 1 – 5 As such, major practice guidelines, including those of NCCN, acknowledge the need to evaluate for HCC bone

Full access

Role of Interventional Radiology in the Treatment of Patients with Neuroendocrine Metastases in the Liver

Larry K. Kvols, Kiran K. Turaga, Jonathan Strosberg, and Junsung Choi

J Gastroenterol 2005 ; 11 : 7676 – 7683 . 7 Sutcliffe R Maguire D Ramage J . Management of neuroendocrine liver metastases . Am J Surg 2004 ; 187 : 39 – 46 . 8 Pichlmayr R Weimann A Oldhafer KJ . Appraisal of

Full access

Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States

Benjamin H. Kann, Henry S. Park, Skyler B. Johnson, Veronica L. Chiang, and James B. Yu

More than 20% of patients with cancer will develop brain metastases. 1 Primary malignancies most commonly associated with brain metastases are lung, breast, and gastrointestinal cancers and melanoma, constituting up to 80% of brain metastases. 1

Full access

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series

Jacob Strelnikov, Alice Zhou, Omar Butt, Michael Ansstas, and George Ansstas

: FLAIR, fluid attenuated inversion recovery; SWI, susceptibility weighted imaging. Discussion Melanoma Brain Metastases Patients with metastatic melanoma have a poor 27% 5-year survival, 28% of whom will develop brain metastases. 1 Risk

Full access

The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series

Michelle C. Nguyen, Manisha H. Shah, David A. Liebner, Floor J. Backes, John Phay, and Lawrence A. Shirley

for melanoma metastases to the lung, liver, subcutaneous and peritoneal tissue, and lymph nodes. The objective response appears to be highest for smaller metastatic lesions and those to the lung, with the most variable responses seen in the liver. 11